Literature DB >> 23194118

Intravesical therapies for bladder cancer - indications and limitations.

Callum Logan1, Matthew Brown, Dickon Hayne.   

Abstract

• Intravesical therapy is a well-established treatment option for non-muscle-invasive bladder cancer (NMIBC). • Choosing the appropriate intravesical agent, schedule and duration of treatment has long been an area of debate. • We review the intravesical agents that are currently used in the management of NMIBC and examine the indications and limitations of their use. • Given the relative high rates of toxicity, failure and non-completion of traditional treatments we also examine some of the newer treatment options available.
© 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23194118     DOI： 10.1111/j.1464-410X.2012.11619.x

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


  11 in total

1.  Recovery of urothelial mediator release but prolonged elevations in interleukin-8 and nitric oxide secretion following mitomycin C treatment.

Authors:  Sung Hyun Kang; Russ Chess-Williams; Shailendra Anoopkumar-Dukie; Catherine McDermott
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-02-03       Impact factor: 3.000

Review 2.  Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage.

Authors:  Adithya Balasubramanian; Ashray Gunjur; Andrew Weickhardt; Nathan Papa; Damien Bolton; Nathan Lawrentschuk; Marlon Perera
Journal:  World J Urol       Date:  2022-01-27       Impact factor: 4.226

3.  Tissue Permeability Effects Associated with the Use of Mucoadhesive Cationic Nanoformulations of Docetaxel in the Bladder.

Authors:  Rakhi Pandey; John K Jackson; Clement Mugabe; Richard Liggins; Helen M Burt
Journal:  Pharm Res       Date:  2016-04-18       Impact factor: 4.200

4.  TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.

Authors:  P Sivaramakrishna Rachakonda; Ismail Hosen; Petra J de Verdier; Mahdi Fallah; Barbara Heidenreich; Charlotta Ryk; N Peter Wiklund; Gunnar Steineck; Dirk Schadendorf; Kari Hemminki; Rajiv Kumar
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-07       Impact factor: 11.205

Review 5.  The effects and effectiveness of electromotive drug administration and chemohyperthermia for treating non-muscle invasive bladder cancer.

Authors:  S E Slater; P Patel; R Viney; M Foster; E Porfiri; N D James; B Montgomery; R T Bryan
Journal:  Ann R Coll Surg Engl       Date:  2014-09       Impact factor: 1.891

Review 6.  Oncolytic virotherapy for urological cancers.

Authors:  Zahid Delwar; Kaixin Zhang; Paul S Rennie; William Jia
Journal:  Nat Rev Urol       Date:  2016-05-24       Impact factor: 14.432

7.  Disseminated Mycobacterium bovis Infection Complicating Intravesical BCG Instillation for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder.

Authors:  Fatehi Elzein; Nada Albogami; Mustafa Saad; Nazik El Tayeb; Abdullah Alghamdi; Ghaleb Elyamany
Journal:  Clin Med Insights Case Rep       Date:  2016-08-16

Review 8.  Treatment options in non-muscle-invasive bladder cancer after BCG failure.

Authors:  Nathan A Brooks; Michael A O'Donnell
Journal:  Indian J Urol       Date:  2015 Oct-Dec

9.  Lidocaine enhances the effects of chemotherapeutic drugs against bladder cancer.

Authors:  Xihua Yang; Lili Zhao; Meiping Li; Lei Yan; Shengwan Zhang; Zhenguo Mi; Liansheng Ren; Jun Xu
Journal:  Sci Rep       Date:  2018-01-12       Impact factor: 4.379

10.  Transperineal cryotherapy for unresectable muscle invasive bladder cancer: preliminary experience with 7 male patients.

Authors:  Qing Zhang; Shiwei Zhang; Shun Zhang; Wei Wang; Xiaozhi Zhao; Yongming Deng; Huibo Lian; Hongqian Guo
Journal:  BMC Urol       Date:  2017-09-09       Impact factor: 2.264
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.